

ACCELERON PHARMA INC  
Form 8-K  
February 26, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 26, 2014**

---

**ACCELERON PHARMA INC.**

(Exact name of Registrant as specified in its charter)

|   |                          |  |
|---|--------------------------|--|
| <b>Delaware</b>                                   | <b>001-36065</b>         | <b>27-0072226</b>                          |
| (State or other<br>jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer<br>Identification Number) |
| <b>128 Sidney Street</b>                          |                          | <b>02139</b>                               |
| <b>Cambridge, MA</b>                              |                          | (Zip Code)                                 |
| (Address of principal)                            |                          |  |

Edgar Filing: ACCELERON PHARMA INC - Form 8-K

executive offices)

Registrant's telephone number, including area code: **(617) 649-9200**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 2.02 Results of Operations and Financial Condition.**

On February 26, 2014, Acceleron Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended December 31, 2013. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information contained in this Item, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed filed for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

99.1 Press Release of Acceleron Pharma Inc. dated February 26, 2014.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACCELERON PHARMA INC.

By: */s/ John D. Quisel*  
John D. Quisel  
Vice President, General Counsel and Secretary

Date: February 26, 2014

**EXHIBIT INDEX**

**Exhibits.**

99.1 Press Release of Acceleron Pharma Inc. dated February 26, 2014.